Cover Image
市場調查報告書

Progenics Pharmaceuticals, Inc.- 產品平台檢討

Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 200993
出版日期 內容資訊 英文 36 Pages
訂單完成後即時交付
價格
Back to Top
Progenics Pharmaceuticals, Inc.- 產品平台檢討 Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年05月27日 內容資訊: 英文 36 Pages
簡介

Progenics Pharmaceuticals, Inc.是開發並產品化癌症治療藥的生物製藥企業。該公司第1號產品化的RELISTOR是有名的Opioids(類鴉片物質)誘發性便秘治療藥。

本報告提供Progenics Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Progenics Pharmaceuticals, Inc.的基本資料

Progenics Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

Progenics Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Progenics Pharmaceuticals, Inc.:開發平台(管線)的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Progenics Pharmaceuticals, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Progenics Pharmaceuticals, Inc.:藥物簡介

  • methylnaltrexone bromide
  • Edotreotide Labeled Yttrium 90
  • iobenguane I 131
  • PSMA ADC
  • MIP-1095
  • MIP-1375
  • MIP-1407
  • PSMA-KLH Conjugate Vaccines

Progenics Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Progenics Pharmaceuticals, Inc.:最近的開發平台趨勢

Progenics Pharmaceuticals, Inc.:暫停中的計劃

Progenics Pharmaceuticals, Inc.:中止開發的開發中產品

  • 中止開發的開發中產品簡介
    • PRO-206
    • PSMA VRP Vaccine

Progenics Pharmaceuticals, Inc.:企業發表

Progenics Pharmaceuticals, Inc.:總公司和子公司的所地

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07132CDB

Summary

Global Markets Direct's, 'Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Progenics Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Progenics Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Progenics Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Progenics Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Progenics Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Progenics Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Progenics Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Progenics Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Progenics Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Progenics Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Progenics Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Progenics Pharmaceuticals, Inc. Snapshot
    • Progenics Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Progenics Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Progenics Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Progenics Pharmaceuticals, Inc. - Pipeline Products Glance
    • Progenics Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Progenics Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Progenics Pharmaceuticals, Inc. - Drug Profiles
    • Edotreotide Labeled Yttrium 90
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • iobenguane sulfate I 131
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PSMA ADC
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MIP-1095
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Progenics Pharmaceuticals, Inc. - Pipeline Analysis
    • Progenics Pharmaceuticals, Inc. - Pipeline Products by Target
    • Progenics Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Progenics Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Progenics Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Progenics Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Progenics Pharmaceuticals, Inc. - Dormant Projects
  • Progenics Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • PSMA VRP Vaccine
  • Progenics Pharmaceuticals, Inc. - Company Statement
  • Progenics Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Progenics Pharmaceuticals, Inc., Key Information
  • Progenics Pharmaceuticals, Inc., Key Facts
  • Progenics Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Progenics Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Progenics Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Progenics Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Progenics Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Progenics Pharmaceuticals, Inc. - Phase II, 2015
  • Progenics Pharmaceuticals, Inc. - Preclinical, 2015
  • Progenics Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Progenics Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Progenics Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Progenics Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Progenics Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Progenics Pharmaceuticals, Inc. - Dormant Developmental Projects,2015
  • Progenics Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015
  • Progenics Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Progenics Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Progenics Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Progenics Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Progenics Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Progenics Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Progenics Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Progenics Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top